ClinicalTrials.gg
Sign In
Biological

CEA-MUC-1-TRICOM Vaccine CV301 clinical trials

Also written CV301.

studies test it
5
open now
0
in phase 3
0
first study started
2013

How each study uses CEA-MUC-1-TRICOM Vaccine CV301 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

CV301
4

Studies by the year they started

5 studies that test it; most in 2018 (2)

Studies that test CEA-MUC-1-TRICOM Vaccine CV301, by start year
YearStudies
20131
20161
20182
20201

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Urinary Bladder Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
1

Who runs them

Industry 2 · Other 3

National Cancer Institute (NCI) (2) · Bavarian Nordic (2) · Georgetown University (1)

Often tested with

Tested in the same studies.

Bintrafusp alfa (1) · Nogapendekin alfa inbakicept (1)

Studies

Open first, then newest update. How each study uses CEA-MUC-1-TRICOM Vaccine CV301 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 5

Given beside what is tested · 1 — CEA-MUC-1-TRICOM Vaccine CV301 is usual care or a partner of the new treatment